WT1-Related Wilms Tumor Syndromes
Symptoms, Doctors, Treatments, Advances & More

  • Overview
  • Find a Doctor
  • Latest Advances
  • Clinical Trials
  • Treatments

Learn About WT1-Related Wilms Tumor Syndromes

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top WT1-Related Wilms Tumor Syndromes Local Doctors?
ZB
Zwi N. Berneman
Elite
Highly rated in
13
conditions

UZ Antwerpen

Edegem, BE 

Zwi Berneman practices in Edegem, Belgium. Berneman is rated as an Elite expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. They are also highly rated in 13 other conditions, according to our data. Their top areas of expertise are WT1-Related Wilms Tumor Syndromes, Wilms Tumor, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

HS
Haruo Sugiyama
Elite
Highly rated in
8
conditions

Osaka University Graduate School Of Medicine

Suita, JP 

Haruo Sugiyama practices in Suita, Japan. Sugiyama is rated as an Elite expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Wilms Tumor, Familial Wilms Tumor 2, Renal Cell Carcinoma (RCC), and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn more
DS
Dr. David A. Scheinberg
Oncology
Elite
Highly rated in
4
conditions
Oncology

Schwartz Research Building

1250 1st Avenue, 
New York, NY 

David Scheinberg is an Oncologist in New York, New York. Scheinberg has been practicing medicine for over 40 years and is rated as an Elite expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 4 other conditions, according to our data. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Wilms Tumor, Leukemia, and Acute Myeloid Leukemia (AML). He is licensed to treat patients in New York.

View All Doctors
What are the Latest Advances for WT1-Related Wilms Tumor Syndromes?
Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.
Condition: Acute Leukemia
Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Treatment Used: Dendritic Cells Based Immunotherapy
Number of Patients: 11
Published: March 06, 2022
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.
Condition: WT1-Positive Tumors
Journal: Scientific reports
Treatment Used: WT2725 WT1-Derived Oligopeptide Vaccine
Number of Patients: 44
Published: November 17, 2021
Tired of the same old research?
Check Latest Advances
Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.
Condition: Elderly Patients with Acute Myeloid Leukemia (AML)
Journal: Cancer immunology, immunotherapy : CII
Treatment Used: Wilms' Tumor 1 Helper Peptide OCV-501
Number of Patients: 19
Published: October 22, 2021
View All Latest Advances
What are the latest WT1-Related Wilms Tumor Syndromes Clinical Trials?
Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
Who is this study for: Patients with mesothelioma
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Biological, Drug
Study Drugs: Galinpepimut-SNivolumabSargramostim
Study Phase: Phase 1

Summary: The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
Who is this study for: Patients with Wilms' tumor protein 1-targeted dendritic cell vaccinations for malignant pleural mesothelioma
Enrollment Status: Recruiting
Publish Date: November 04, 2022
Intervention Type: Biological
Study Drug: Dendritic cell vaccination+Chemotherapy
Study Phase: Phase 1/Phase 2

Summary: In this multicenter phase I/II trial, dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be used in conjunction with conventional chemotherapy for the frontline treatment of malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with WT1-...

View All Clinical Trials
Better Care. Faster.
  • How MediFind Works
  • Our Story
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Newsroom
  • Partnering With Us
  • Contact Us
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

By subscribing, I agree to MediFind's Terms & Conditions and Privacy Policy.

  • FAQ
  • Feedback
  • Advertising Policy
  • Privacy Policy
  • Terms & Conditions
Follow Us On
MediFindBetter Care. Faster.
© 2023 All Rights Reserved.

This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.